

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

New isoprenylated flavonoids and cytotoxic constituents from *Artocarpus tonkinensis*

Jian-Ping Ma^a; Xin Qiao^a; Shu Pan^a; Hong Shen^a; Guo-Fu Zhu^b; Ai-Jun Hou^a

^a Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai, China ^b School of Chinese Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Online publication date: 13 July 2010

To cite this Article Ma, Jian-Ping , Qiao, Xin , Pan, Shu , Shen, Hong , Zhu, Guo-Fu and Hou, Ai-Jun(2010) 'New isoprenylated flavonoids and cytotoxic constituents from *Artocarpus tonkinensis*', Journal of Asian Natural Products Research, 12: 7, 586 – 592

To link to this Article: DOI: 10.1080/10286020.2010.485932

URL: <http://dx.doi.org/10.1080/10286020.2010.485932>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ORIGINAL ARTICLE

New isoprenylated flavonoids and cytotoxic constituents from *Artocarpus tonkinensis*

Jian-Ping Ma^a, Xin Qiao^a, Shu Pan^a, Hong Shen^a, Guo-Fu Zhu^b and Ai-Jun Hou^{a*}

^aDepartment of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, China;

^bSchool of Chinese Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

(Received 19 January 2010; final version received 13 April 2010)

Two new isoprenylated flavonoids, artotonins A and B (**1** and **2**), along with 13 known compounds (**3–15**), were isolated from the roots of *Artocarpus tonkinensis* A. Chev. ex Gagnep. The structures were elucidated by spectroscopic methods. Cyclocommunol (**6**), isocyclomulberrin (**7**), cudraflavone C (**11**), and morusin (**13**) exhibited cytotoxicity against hepatocellular carcinoma (SMMC-7721) and gastric carcinoma (BGC-823 and SGC-7901) cell lines.

Keywords: *Artocarpus tonkinensis*; isoprenylated flavonoids; artotonins A and B; cytotoxicity

1. Introduction

Artocarpus species are rich in isoprenylated phenolic compounds, including flavonoids, 2-arylbenzofurans, and stilbenoids, some compounds showing antimycobacterial, antimalarial, and anti-inflammatory effects as well as cyclooxygenase- and tyrosinase-inhibitory activities [1–5]. Recently, our group reported a variety of cytotoxic prenylated flavonoids and 2-arylbenzofurans from *Artocarpus chama* and *Artocarpus petelotii* [6–8]. In our program searching for bioactive compounds from *Artocarpus* plants, the roots of *Artocarpus tonkinensis* A. Chev. ex Gagnep were collected in the Yunnan Province, China. The leaves and bark of *A. tonkinensis* are used as traditional medicine in Vietnam to treat backache and rheumatism. A few flavonoid glycosides with anti-inflammatory effects and benzofurans were isolated from this plant previously [9–11].

Our preliminary bioassay showed that the ethanol extract from the roots of *A. tonkinensis* exhibited cytotoxicity against hepatocellular carcinoma (SMMC-7721) and gastric carcinoma (BGC-823 and SGC-7901) cell lines. Further separation of this extract afforded two new isoprenylated flavonoids, artotonins A and B (**1** and **2**), along with 13 known compounds, i.e. artoheterophyllin D (**3**) [12], artoindonesianin X (**4**) [13], artonin A (**5**) [14], cyclocommunol (**6**) [15], isocyclomulberrin (**7**) [16], norartocarpetin (**8**) [17], kaempferol (**9**) [18], albanin A (**10**) [19], cudraflavone C (**11**) [19], 3'',3''-dimethylpyrano[3',4']2,4,2'-trihydroxychalcone (**12**) [3], morusin (**13**) [15], (+)-catechin (**14**) [20], and (+)-afzelechin-3-*O*- α -L-rhamnopyranoside (**15**) [21] (Figure 1). Compounds **4–7**, **9**, and **11–15** were screened for cytotoxicity against SMMC-7721, BGC-823, and

*Corresponding author. Email: ajhou@shmu.edu.cn

Table 1. ^1H and ^{13}C NMR spectral data of **1** and **2** (in $(\text{CD}_3)_2\text{CO}$, δ in ppm, J in Hz).

Position	1 ^a		2 ^b	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}
2	5.76 (dd, $J = 2.6, 13.3$)	76.3		162.2
3	3.05 (dd, $J = 13.3, 16.7$), 2.74 (dd, $J = 2.6, 16.7$)	43.6		122.8
4		191.0		183.2
5	7.67 (d, $J = 8.6$)	128.3		163.4
6	6.49 (d, $J = 8.6$)	111.3	6.23 (br s)	99.1
7		159.9		164.6
8		110.3	6.31 (br s)	94.1
9		159.0		159.2
10		115.8		105.1
1'		117.8		113.0
2'		156.3		157.1
3'	6.49 (d, $J = 2.3$)	103.6	6.55 (br s)	103.9
4'		159.5		161.3
5'	6.45 (dd, $J = 2.3, 8.4$)	108.0	6.51 (br d, $J = 8.0$)	108.0
6'	7.36 (d, $J = 8.4$)	128.8	7.22 (d, $J = 8.0$)	132.1
11	6.63 (d, $J = 10.0$)	116.5	2.46 (t, $J = 8.4$)	21.1
12	5.72 (d, $J = 10.0$)	129.9	1.61 (t, $J = 8.4$)	43.0
13		78.1		70.1
14	1.43 (s)	28.2	1.06 (s)	29.3
15	1.45 (s)	28.5	1.06 (s)	29.3
5-OH			13.18 (s)	
7-OH			9.55 (br s) ^c	
2'-OH	8.60 (br s) ^c		8.75 (br s) ^c	
4'-OH	8.35 (br s) ^c		8.75 (br s) ^c	
13-OH			3.17 (s)	

Note: ^a 500 MHz.^b 400 MHz.^c Signals may be exchangeable.

SGC-7901 cell lines. In this paper, we have described the structural elucidation of the new compounds (**1** and **2**) and cytotoxicity evaluation.

2. Results and discussion

Artotonin A (**1**), an optically active compound ($[\alpha]_{\text{D}}^{20} = -19.2$), was isolated as a yellow amorphous powder. Its molecular formula was deduced as $\text{C}_{20}\text{H}_{18}\text{O}_5$ by HR-EI-MS at m/z 338.1160 $[\text{M}]^+$. The IR spectrum showed absorption bands for hydroxyl (3342 cm^{-1}), carbonyl (1660 cm^{-1}), and aromatic ring (1594 , 1517 , and 1462 cm^{-1}) moieties. The ^1H NMR spectrum exhibited signals of two hydroxyl groups at δ_{H} 8.60 and 8.35 (each

1H, br s), two *ortho*-coupled protons at δ_{H} 7.67 and 6.49 (each 1H, d, $J = 8.6$ Hz), an ABX spin aromatic system at δ_{H} 7.36 (1H, d, $J = 8.4$ Hz), 6.49 (1H, d, $J = 2.3$ Hz), and 6.45 (1H, dd, $J = 2.3, 8.4$ Hz), and a 2,2-dimethylpyran ring at δ_{H} 6.63, 5.72 (each 1H, d, $J = 10.0$ Hz) and 1.45, 1.43 (each 3H, s) (Table 1). Furthermore, signals of another ABX spin system at δ_{H} 5.76 (1H, dd, $J = 2.6, 13.3$ Hz, H-2), 3.05 (1H, dd, $J = 13.3, 16.7$ Hz, H-3), and 2.74 (1H, dd, $J = 2.6, 16.7$ Hz, H-3) were characteristic of ring C on a flavanone skeleton. The ^{13}C NMR and HMQC spectra showed 20 carbon signals attributable to one carbonyl group, seven quaternary sp^2 , one quaternary sp^3 , seven methine sp^2 , one methine sp^3 , one methylene sp^3 ,




Figure 1. Structures of compounds 1–15.

and two methyl carbon atoms. These NMR spectroscopic data suggest that **1** is a monoprenylated and dihydroxylated flavanone. The two *ortho*-coupled protons at δ_{H} 7.67 and 6.49 were assigned to H-5 and H-6, respectively, as established by the HMBC correlations from H-5 (δ_{H} 7.67) to C-4 (δ_{C} 191.0), C-7 (δ_{C} 159.9), and C-9 (δ_{C} 159.0), and from H-6 (δ_{H} 6.49) to C-8 (δ_{C} 110.3) and C-10 (δ_{C} 115.8) (Figure 2). The HMBC correlations from H-11 (δ_{H}

6.63) to C-7 and from H-12 (δ_{H} 5.72) to C-8 indicated that the 2,2-dimethylpyran ring was fused to C-7 and C-8. The 2',4'-dihydroxy substitution in ring B was deduced by the HMBC correlations from H-2 (δ_{H} 5.76) to C-1' (δ_{C} 117.8) and C-6' (δ_{C} 128.8), from H-5' (δ_{H} 6.45) to C-1' and C-3' (δ_{C} 103.6), and from H-6' (δ_{H} 7.36) to C-2' (δ_{C} 156.3) and C-4' (δ_{C} 159.5). The configuration at C-2 was proposed as *S* according to the specific optical rotation of




Figure 2. Selected HMBC (H → C) correlations of compound **1**.

1 ($[\alpha]_D^{20} = -19.2$) and the *trans*-diaxial coupling constant of H-2 and H-3 ($J = 13.3$ Hz) [22]. Thus, the structure of artotonin A was elucidated as (2*S*)-2',4'-dihydroxy-2'',2''-dimethylpyrano-(7,8:6'',5'')flavanone (Figure 1).

Artotonin B (**2**), a yellow amorphous powder, was assigned a molecular formula of $C_{20}H_{20}O_7$ by HR-EI-MS at m/z 372.1215 $[M]^+$. The 1H NMR spectrum contained signals of a hydrogen-bonded hydroxyl group at δ_H 13.18 (1H, s), three phenolic hydroxyl groups at δ_H 9.55 (1H, br s) and 8.75 (2H, br s), an ABX spin system at δ_H 7.22 (1H, d, $J = 8.0$ Hz), 6.55 (1H, br s), and 6.51 (1H, br d, $J = 8.0$ Hz), and two broad singlets at δ_H 6.31 and 6.23 (each 1H, br s), which were derived from a 5,7,2',4'-tetrahydroxylated flavone. Moreover, a 3-hydroxy-3-methylbutyl group was inferred from the following 1H and ^{13}C NMR spectral data at δ_H 3.17 (13-OH,




Figure 3. Selected HMBC (H → C) correlations of compound **2**.

s), 2.46 (2H, t, $J = 8.4$ Hz, H₂-11), 1.61 (2H, t, $J = 8.4$ Hz, H₂-12), and 1.06 (6H, s, H₃-14, 15), as well as δ_C 21.1 (C-11), 43.0 (C-12), 70.1 (C-13), and 29.3 (C-14, 15). This isoprenoid group was attached at C-3 according to the HMBC correlations from CH₂-11 to C-2 (δ_C 162.2), C-3 (δ_C 122.8), and C-4 (δ_C 183.2), and from CH₂-12 to C-3 (Figure 3). The substitution of rings A and B was further supported by the HMBC correlations shown in Figure 3. Thus, the structure of artotonin B was elucidated as 5,7,2',4'-tetrahydroxy-3-(3-hydroxy-3-methylbutyl)flavone (Figure 1).

Compounds **4–7**, **9**, and **11–15** were evaluated for *in vitro* cytotoxicity against SMMC-7721, SGC-7901, and BGC-823 cell lines (Table 2). In this test, *cis*-platinum was used as a positive control. The results showed that isoprenylated flavones (**6**, **7**, **11**, and **13**), except **5**,

Table 2. IC₅₀ (\pm SD) values (μ M) of compounds against human carcinoma cells.

Compound	SMMC-7721	BGC-823	SGC-7901
4	NA	NA	NA
5	NA	NA	NA
6	16.1 \pm 1.5	27.1 \pm 2.8	79.7 \pm 8.5
7	19.5 \pm 1.4	33.1 \pm 4.1	14.2 \pm 2.3
9	NA	NA	NA
11	11.8 \pm 0.9	24.9 \pm 1.7	35.5 \pm 3.7
12	NA	NA	NA
13	20.6 \pm 2.4	12.6 \pm 1.1	75.8 \pm 4.4
14	NA	NA	NA
15	NA	NA	NA
<i>cis</i> -platinum	6.3 \pm 0.6	7.3 \pm 0.9	14.1 \pm 1.3

Note: NA, not active.

exhibited inhibitory effects on three kinds of carcinoma cells. On the other hand, isoprenylated 2-arylbenzofuran (**4**) and chalcone (**12**), as well as nonprenylated flavone (**9**), flavanol, and its glycoside (**14** and **15**), were inactive.

3. Experimental

3.1 General experimental procedures

The UV spectra were determined on a Shimadzu UV-2401PC spectrophotometer, and IR spectra were measured on a Nicolet Avatar-360 spectrometer. Optical rotation was determined on a Jasco P1030 polarimeter. The 1D and 2D NMR spectra were recorded on Bruker DRX-500 and Varian Mercury Plus 400 instruments, using residual solvent peaks of $(\text{CD}_3)_2\text{CO}$ (δ_{H} 2.04, δ_{C} 206.0) or Me_4Si as an internal standard. Chemical shifts (δ) were reported in ppm and coupling constants (J) in Hz. EI-MS and HR-EI-MS measurements were carried out on a Finnigan MAT-95 mass spectrometer. Column chromatography (CC) was performed on silica gel H (10–40 μm and 200–300 mesh; Institute of Chemical Technology, Yantai, China), Diaion HP-20 (Mitsubishi Chemical Co., Tokyo, Japan), MCI gel CHP-20P (75–150 μm , Mitsubishi Chemical Co.), Chromatorex RP-18 gel (20–45 μm ; Fuji Silysia Chemical Ltd, Kasugai, Japan), Toyoparl HW-40C gel (Tosoh Co., Tokyo, Japan), and Sephadex LH-20 gel (GE Healthcare Amersham Biosciences, Uppsala, Sweden). TLC analysis was run on precoated silica gel GF₂₅₄ plates (10–40 μm ; Institute of Chemical Technology, Yantai, China). Preparative HPLC was performed on Agilent 1200 (Agilent Technologies, Santa Clara, CA, USA) and YMC C₁₈ column (10 \times 250 mm, 5 μm ; YMC Co., Kyoto, Japan).

3.2 Plant material

The roots of *A. tonkinensis* A. Chev. ex Gagnep were collected in Xishuangbanna,

Yunnan Province, China, in July 1998, and air-dried. The plant was identified by Prof. Han-Dong Sun, Kunming Institute of Botany, and a voucher specimen (TCM 98-07-03 Hou) has been deposited at the Herbarium of the Department of Pharmacognosy, School of Pharmacy, Fudan University, China.

3.3 Extraction and isolation

The dried and powdered roots (6.35 kg) of *A. tonkinensis* were percolated with 95% EtOH (90 liters) at room temperature. The filtrate was evaporated *in vacuo* to give a residue (800 g), which was suspended in H₂O and extracted successively with petroleum ether and EtOAc. The petroleum ether extract (73 g) was subjected to CC on silica gel eluted with a gradient of petroleum ether–EtOAc (4:1, 7:3, 3:2, 1:1, 2:3) to yield fractions 1–12. Fraction 5 (3.19 g) was isolated by CC on a silica gel eluted with a gradient of CHCl_3 –*i*-PrOH (150:1, 100:1, 60:1, 30:1) to provide fractions 5.1–5.8. Fraction 5.2 (580 mg) was purified by CC on silica gel (CHCl_3 –EtOAc 25:1), followed by CC on RP-18 (MeOH–H₂O 7:3) to afford **4** (40 mg). Fraction 5.3 (274 mg) was separated by CC on MCI gel CHP-20P (MeOH–H₂O 3:2, 4:1, 9:1) to afford **5** (2 mg). Fraction 5.5 (491 mg) was fractionated by CC on silica gel (petroleum ether–Me₂CO 5:1), then by preparative HPLC (flow rate 1.0 ml/min, UV detector 254 nm) using 90% MeOH to yield **7** (5 mg, t_{R} 40 min) and **11** (8 mg, t_{R} 23 min). Fraction 5.8 (305 mg) was isolated by CC on silica gel (petroleum ether–Me₂CO 5:1), followed by CC on RP-18 (MeOH–H₂O 3:1) to yield **13** (24 mg) and **6** (12 mg). Fraction 6 (218 mg) was subjected to CC on silica gel (petroleum ether–EtOAc 3:1) to afford **3** (2 mg). Fraction 7 (512 mg) was purified by CC on silica gel (petroleum ether–Me₂CO 3:1), followed by preparative HPLC (flow rate 1.0 ml/min, UV detector 254 nm) using 90% MeOH to give **1** (2 mg,

t_R 20 min) and **12** (7 mg, t_R 23 min). Fraction 9 (296 mg) was isolated by CC on silica gel (CHCl_3 -*i*-PrOH 20:1) to give **10** (1 mg).

The EtOAc extract (260 g) was separated by CC on Diaion HP-20 (MeOH-H₂O 1:4, 2:3, 3:2, 4:1) to yield fractions 13-17. Fraction 13 (8 g) was subjected to CC on silica gel (CHCl_3 -MeOH-H₂O 90:20:1) to give fractions 13.1-13.14. Fraction 13.8 (1.5 g) was purified by CC on Toyopearl HW-40C (MeOH-H₂O 1:9, 1:4, 3:7, 2:3) to yield **14** (10 mg) and **15** (35 mg). Fraction 16 (13 g) was subjected to CC on silica gel (CHCl_3 -MeOH-H₂O 85:15:1) to yield fractions 16.1-16.7. Fraction 16.2 (500 mg) was separated by CC on silica gel (petroleum ether-Me₂CO 3:1) to provide **9** (8 mg). Fraction 16.3 (320 mg) was purified by CC on silica gel (petroleum ether-Me₂CO 2:1), followed by CC on Sephadex LH-20 (CHCl_3 -MeOH 2:1) to afford **2** (4 mg) and **8** (7 mg).

3.3.1 Artotonin A (**1**)

A yellow amorphous powder; $[\alpha]_D^{20} = -19.2$ ($c = 0.04$, MeOH); UV (MeOH) λ_{\max} (log ϵ): 205 (3.96), 265 (4.25), 310 (3.77) nm; IR (KBr) ν_{\max} : 3342, 2924, 1660, 1594, 1517, 1462, 1441, 1377, 1278, 1112 cm^{-1} ; ¹H and ¹³C NMR spectral data, see Table 1; EI-MS m/z (%): 338 (7, [M]⁺), 320 (19), 305 (53), 242 (100), 213 (15), 187 (44); HR-EI-MS m/z : 338.1160 [M]⁺ (calcd for C₂₀H₁₈O₅, 338.1154).

3.3.2 Artotonin B (**2**)

A yellow amorphous powder; UV (MeOH) λ_{\max} (log ϵ): 211 (4.19), 259 (4.34), 297 (3.99) nm; IR (film) ν_{\max} : 3452, 2970, 2931, 1655, 1616, 1507, 1457, 1359, 1162 cm^{-1} ; ¹H and ¹³C NMR spectral data, see Table 1; EI-MS m/z (%): 372 (4, [M]⁺), 354 (51), 311 (100), 299 (24), 207 (15); HR-EI-MS m/z : 372.1215 [M]⁺ (calcd for C₂₀H₂₀O₇, 372.1209).

3.4 Cytotoxicity assay

Compounds were tested for cytotoxicity against hepatocellular carcinoma (SMMC-7721) and gastric carcinoma (SGC-7901 and BGC-823) cell lines by the MTT assay according to a reported procedure [23].

Acknowledgement

This study was financially supported by the National Natural Science Foundation of China (30572247) and the Key National Scientific and Technological Program 'Major New Drug Development' of the Ministry of Science and Technology of the PR China (No. 2009ZX09301-011).

References

- [1] B.N. Su, M. Cuendet, M.E. Hawthorne, L.B.S. Kardono, S. Riswan, H.H.S. Fong, R.G. Mehta, J.M. Pezzuto, and A.D. Kinghorn, *J. Nat. Prod.* **65**, 163 (2002).
- [2] A. Puntumchai, P. Kittakoop, S. Rajvir-oongit, S. Vimuttipong, K. Likhitwitaya-wuid, and Y. Thebtaranonth, *J. Nat. Prod.* **67**, 485 (2004).
- [3] A.R. Han, Y.J. Kang, T. Windono, S.K. Lee, and E.K. Seo, *J. Nat. Prod.* **69**, 719 (2006).
- [4] A. Widyawaruyanti, Subehan, S.K. Kalauni, S. Awale, M. Nindatu, N.C. Zaini, D. Syafruddin, P.B.S. Asih, Y. Tezuka, and S. Kadota, *J. Nat. Med.* **61**, 410 (2007).
- [5] Z.P. Zheng, K.W. Cheng, J.T.K. To, H. Li, and M.F. Wang, *Mol. Nutr. Food Res.* **52**, 1530 (2008).
- [6] Y.H. Wang, A.J. Hou, L. Chen, D.F. Chen, H.D. Sun, Q.S. Zhao, K.F. Bastow, Y. Nakanish, X.H. Wang, and K.H. Lee, *J. Nat. Prod.* **67**, 757 (2004).
- [7] Y.H. Wang, A.J. Hou, D.F. Chen, M. Weiller, A. Wendel, and R.J. Staples, *Eur. J. Org. Chem.* **15**, 3457 (2006).
- [8] H. Shen and A.J. Hou, *Nat. Prod. Res.* **22**, 1451 (2008).
- [9] T.P. Lien, H. Ripperger, A. Porzel, T.V. Sung, and G. Adam, *Pharmazie* **53**, 353 (1998).
- [10] T.T. Thuy, C. Kamperdick, P.T. Ninh, T.P. Lien, T.T.P. Thao, and T.V. Sung, *Pharmazie* **59**, 297 (2004).
- [11] D.T.N. Dang, E. Eriste, E. Liepinsh, T.T. Trinh, H. Erlandsson-Harris, R. Sillard,

- and P. Larsson, *Scand. J. Immunol.* **69**, 110 (2009).
- [12] Z.P. Zheng, S. Chen, S. Wang, X.C. Wang, K.W. Cheng, J.J. Wu, D. Yang, and M. Wang, *J. Agric. Food Chem.* **57**, 6649 (2009).
- [13] N.H. Soekamto, S.A. Achmad, E.L. Ghisalberti, E.H. Hakim, and Y.M. Syah, *Phytochemistry* **64**, 831 (2003).
- [14] Y. Hano, M. Aida, M. Shiina, T. Nomura, T. Kawai, H. Ohe, and K. Kagei, *Heterocycles* **29**, 1447 (1989).
- [15] L. Wang, H.Q. Wang, and R.Y. Chen, *China J. Chinese Mater. Med.* **32**, 2497 (2007).
- [16] C.C. Chen, Y.L. Huang, J.C. Ou, C.F. Lin, and T.M. Pan, *J. Nat. Prod.* **56**, 1594 (1993).
- [17] M.L. Gan, S. Ouyang, P. Xie, Y.F. Xiong, and L.M. Chen, *Chinese Tradit. Herb. Drugs* **36**, 988 (2005).
- [18] M.H. Tan, Z.R. Zhang, H.Y. Qin, and J.H. Liu, *Chinese Tradit. Herb. Drugs* **21**, 246 (1990).
- [19] Y. Hano, Y. Matsumoto, K. Shinohara, J.Y. Sun, and T. Nomura, *Heterocycles* **31**, 1339 (1990).
- [20] Y.J. Cui, P. Liu, and R.Y. Chen, *China J. Chinese Mater. Med.* **30**, 121 (2005).
- [21] S.E. Drewes, C.W. Taylor, and A.B. Cunningham, *Phytochemistry* **31**, 1073 (1992).
- [22] S. Kanokmedhakul, K. Kanokmedhakul, K. Nambuddee, and P. Kongsaree, *J. Nat. Prod.* **67**, 968 (2004).
- [23] Y.S. Zou, A.J. Hou, and G.F. Zhu, *Chem. Biodiv.* **2**, 131 (2005).